Home Drugs A to Z S Sp Sporanox Disease Interactions

Sporanox (itraconazole) Disease Interactions

There are 3 disease interactions with Sporanox (itraconazole):

Itraconazole (Includes Sporanox) ↔ Chf

Severe Potential Hazard, High plausibility

Applies to: Renal Dysfunction, Fluid Retention, Heart Disease, Chronic Obstructive Pulmonary Disease

Itraconazole may possess a dose-related negative inotropic effect. Transient, asymptomatic decreases in left ventricular ejection fraction have been observed following intravenous administration in healthy volunteers. Additionally, cases of congestive heart failure (CHF), peripheral edema, and pulmonary edema have been reported during postmarketing use for onychomycosis and/or systemic fungal infections. Therapy with itraconazole is not recommended for the treatment of onychomycosis in patients with evidence of ventricular dysfunction such as CHF or a history of CHF. It is also not recommended for other indications in such patients unless benefit clearly outweighs the risk. Cautious use is advised in patients with risk factors for CHF, including cardiac disease such as ischemic and valvular disease; significant pulmonary disease such as chronic obstructive pulmonary disorder; and renal disease and other edematous disorders. These patients should be informed of and monitored for signs and symptoms of CHF during treatment.


Itraconazole (Includes Sporanox) ↔ Hepatotoxicity

Severe Potential Hazard, Low plausibility

Applies to: Liver Disease

The use of itraconazole has been rarely associated with hepatotoxicity. Reversible idiosyncratic hepatitis and fatalities have been reported, the latter occurring primarily in patients with serious underlying medical conditions and taking multiple concomitant medications. Liver function tests should be performed periodically in patients with preexisting hepatic abnormalities, particularly when itraconazole therapy is administered continuously for more than one month. Therapy should be withdrawn if persistent elevations or worsening of liver enzyme levels occur. Because itraconazole is also extensively metabolized by the liver, patients with liver disease should be monitored carefully during treatment with itraconazole, and the dosing adjusted or discontinued if necessary.


Itraconazole (Includes Sporanox) ↔ Achlorhydria

Moderate Potential Hazard, High plausibility

Applies to: Achlorhydria

The absorption of itraconazole from the capsule formulation diminishes with decreased gastric acidity. Patients with achlorhydria should be advised to take itraconazole capsules with 8 oz. of a cola beverage, which has been shown to enhance absorption in AIDS patients with relative or absolute achlorhydria.


You should also know about...

Sporanox (itraconazole) drug Interactions

There are 428 drug interactions with Sporanox (itraconazole)

Sporanox (itraconazole) alcohol/food Interactions

There is 1 alcohol/food interaction with Sporanox (itraconazole)

See also...

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.

Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.

Do not stop taking any medications without consulting your healthcare provider.


Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

(web3)